Effects of Five Days of Physical Inactivity on Endothelial Function in Healthy Humans
1 other identifier
interventional
8
1 country
1
Brief Summary
Physical inactivity is a significant predictor of major non-communicable diseases such as type 2 diabetes (7%), cardiovascular disease (6%), musculoskeletal disorders and some types of cancer, and has been proposed to be the 4th leading cause of death worldwide. The investigators aim is to assess the vascular (endothelial) function before and after a 5-day period of reduced activity of upper and lower limbs via an arm sling and daily step counts reduction, respectively, in healthy participants. Twelve young (ages of 18 - 35 years), healthy, males and females, recreationally active with a body mass index between 18 and 27 kg/m2 will be recruited. The participants will then randomly undergo two 5-day interventions: (A) 5 consecutive days of habitual daily levels of physical activity and matched food intake (Control trial). (B) 5 consecutive days of reduced step count by 80% compared to the Control trial combined with their non-dominant arm placed in a sling and a reduction in food (energy) intake (\~20%) to match the reduction in energy expenditure induced by inactivity (Inactivity trial). On days 1 and 6 of each experimental trial, the endothelial function of the brachial and popliteal arteries, and hand grip strength will be measured.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2018
CompletedFirst Submitted
Initial submission to the registry
November 19, 2019
CompletedFirst Posted
Study publicly available on registry
December 16, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2020
CompletedFebruary 23, 2022
February 1, 2022
1.3 years
November 19, 2019
February 4, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Change from baseline of flow-mediated vasodilatation (FMD) of the brachial artery
The FMD of the brachial artery will be measured using an ultrasound collected at baseline and continuously for 80 seconds post-arm occlusion for 5 minutes
Over 6 minutes and 20 seconds on day 1 and day 6 of each study arm
Change from baseline of flow-mediated vasodilatation (FMD) of the popliteal artery
The FMD of the popliteal artery will be measured using an ultrasound collected at baseline and continuously for 80 seconds post-arm occlusion for 5 minutes
Over 6 minutes and 20 seconds on day 1 and day 6 of each study arm
Secondary Outcomes (1)
Hand grip strength
3 minutes
Study Arms (2)
Control
NO INTERVENTION5 consecutive days of normal daily levels of physical activity and matched food intake
Inactivity
EXPERIMENTAL5 consecutive days of reduced step count by 80% compared to the Control trial, whilst placing the non-dominant arm in a sling, and reduced food intake (\~ 20%) to match the reduction in energy expenditure induced by inactivity
Interventions
On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
Eligibility Criteria
You may qualify if:
- Non-smoking
- Males
- Age (18-35 years old)
- Body mass index (BMI) of 18-27 kg/m2
- Recreationally active
- Ability to give informed consent
You may not qualify if:
- Smoking
- Any metabolic (e.g. diabetes), endocrine (e.g. hyperthyroidism) or cardiovascular (e.g. heart or blood) abnormalities including hypertension or heart failure
- Clinically significant abnormalities on screening including ECG abnormalities
- Taking routine medication that may alter cardiovascular function and blood flow (e.g. blood pressure-lowering drugs or drugs that cause hypertension)
- Well-trained individuals
- On an energy-restricted diet or seeking to lose weight
- High alcohol consumption (\<3-4 units/day)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The University of Nottingham
Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr Moira A Taylor
Study Record Dates
First Submitted
November 19, 2019
First Posted
December 16, 2019
Study Start
November 1, 2018
Primary Completion
March 1, 2020
Study Completion
March 1, 2020
Last Updated
February 23, 2022
Record last verified: 2022-02
Data Sharing
- IPD Sharing
- Will not share